NDAINJECTIONINJECTABLE
Approved
Apr 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER (ceftriaxone) by B. Braun is 12. First approved in 2005.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Ceftriaxone and Dextrose in Duplex Container is a ready-to-use injectable formulation combining the third-generation cephalosporin ceftriaxone with dextrose diluent. It is a bactericidal antibiotic that inhibits bacterial cell wall synthesis and is used to treat a broad spectrum of gram-positive and gram-negative infections. The duplex container design eliminates the need for manual mixing, improving convenience in hospital and clinical settings.
LOE Approaching
As a mature generic approaching loss of exclusivity with moderate competitive pressure (30%), teams are typically focused on defensive positioning and operational efficiency rather than growth initiatives.
Mechanism of Action
12.1 Mechanism of Action Ceftriaxone is an antibacterial drug [see ]. 12.3 Pharmacokinetics Average plasma concentrations of ceftriaxone following a single 30-minute intravenous (IV) infusion of a 0.5, 1 or 2 g dose in healthy subjects are presented in Table 2. Multiple IV doses ranging from 0.5 to…
Worked on CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER at B. Braun? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.